The Valley Desk

NCT00699842 · Interventional trial

A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients

Overall registry status Terminated

Phase 1 · Phase 2

Conditions Low to Intermediate-1 MDS, MDS, Myelodysplastic Syndrome, Non-deletion 5q

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov